Molnupiravir: A New Hope For Prevention And Treatment Of Covid-19 And Other Dangerous Viruses

A new Covid-19 therapy has completed its phase two human trial and the results are promising. Molnupiravir, developed by Ridgeback Biotherapeutics LP and Merck & Co., reached its endpoint objective of reducing the length of Covid-19 infections, according to a Merck press release. This endpoint, among others, will be examined in greater depth upon the full data release from the trial.

Respiratory viruses like influenza, respiratory syncytial virus, and now Covid-19 are uniquely challenging to treat once symptoms arise. Because infections and symptoms for respiratory viruses are typically short-lived, the immune system quickly engages in viral replication suppression. Common form antivirals like Tamiflu and Xofluza for the flu, and now Remdesivir and monoclonal antibodies for Covid-19 must be administered within the first few days of infection to reduce symptom severity and infection duration.

Read the full article on Forbes.

© William A. Haseltine, PhD. All Rights Reserved.